A review of the clinical pharmacokinetics of meloxicam

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 13-16

  Turck D ^a   Roth, W ^a   Busch, U ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Absorption; Distribution; Elimination; Interactions; Meloxicam; Metabolism; Pharmacokinetic properties

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; OSTEOARTHRITIS; PHARMACOKINETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029967507     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.13     Document Type: Article

References (28)

1. Distel M, Bluhmki E. Global analysis of safety of meloxicam, a new enolic acid derived non-steroidal anti-inflammatory agent. Rheumatol Eur 1995;24(suppl. 3):390.
2. Engelhardt G. Meloxicam a potent inhibitor of COX-2. Data presented at 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 6-10, 1994, p. 82.
3. Türck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995;15:22-34.
4. Türck D, Busch U, Heinzel G, Narjes H, Nehmiz G. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995;9:270-6.
5. Narjes H, Türck D, Busch U, Heinzel G, Nehmiz G. Tolerability and pharmacokinetics of meloxicam after i.m. administration. Br J Clin Pharmacol 1996;41:135-40.
6. Guentert TW, Defoin R, Mosberg H. The influence of cholestyramine on the elimination of tenoxicam and piroxicam. Eur J Clin Pharmacol 1988;34:283-9.
7. Benveniste C, Striberni R, Dyer P. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. Eur J Clin Pharmacol 1990;38:457-9.
8. Busch H, Heinzel G, Narjes H. Effect of cholestyramine on pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID) in man. 1st International Congress of Inflammation, Barcelona, Spain, June, 17-22, 1990, 283; Eur J Clin Pharmacol 1995;48:269-72.
9. Laufen H, Leitold M. The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharmacol Ther Toxicol 1986;24:48-52.
10. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1987;12:402-32.
11. Verbeeck RK, Loewen GR, Blackburn JL. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1983;8:297-331.
12. Busch U. Pharmacokinetics of meloxicam in animals. Scand J Rheumatol 1994;Suppl 98:abstract no. 119.
13. Degner F, Heinzel G, Busch U. Transsynovial kinetics of meloxicam. Scand J Rheumatol 1994;Suppl 98:abstract no. 121.
14. 14C]meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990;16:49-52.
15. Schmid J, Prox A, Busch U, Kaschke S, Sauter T. The biotransformation of meloxicam in man and rat. Scand J Rheumatol 1994;Suppl 98:abstract no. 118.
16. Hobbs DC. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex and adverse events. Am J Med 1986;81(suppl. 5B):22-8.
17. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994;26:16-43.
18. Wilis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling P. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979;16:405-10.
19. Scheidel B, Blume H, Walter K, Stanislaus F, Babej-Dölle RM. Bioavailability study of enteric coated diclofenac formulations/2nd communication: bioavailability study following single dose administration of multiple unit formulation and a single unit formulation comparing fasted and non fasted conditions. Arzneimittelforschung 1993;43:1211-5.
20. Degner F, Heinzel G, Narjes H, Türck D. The effect of meloxicam on the pharmacokinetics of β-acetyldigoxin. Br J Clin Pharmacol 1995;40:486-8.
21. Hübner G, Sander O, Degner F, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients. Scand J Rheumatol 1994;Suppl 98:abstract no. 108.
22. Busch U, Heinzel G, Narjes H, Nehmiz G. Investigation of interaction of meloxicam with cimetidine, Maalox® or aspirin. J Clin Pharmacol, in press.
23. Müller FO, Schall R, DeVaal AC, Groenewoud G, Hundt HKL, Middle MV. No interaction of meloxicam with either single or multiple repeated doses of furosemide. Eur J Clin Pharmacol 1995;48:247-51.
24. Day RO, Graham GG, Williams KM, Champion GD, De Jager J. Clinical pharmacology of nonsteroidal anti-inflammatory drugs. Pharmacol Ther 1987;33:383-433.
25. Sander O, Hübner G, Türck D, Degner F, Rau R. Meloxicam pharmacokinetics in elderly compared to younger male and female patients with rheumatoid arthritis. Rheumatol Eur 1995;24(suppl. 3):221.
26. Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985;37:13-8.
27. Türck D, Boulton-Jones M, North N, Heinzel G, Nehmiz. G. A phase I study to determine the steady state pharmacokinetics of meloxicam 15 mg capsules in moderate, mild or no renal impairment. Rheumatol Eur 1995;24(suppl. 3):221.
28. Busch U, Heinzel G, Narjes H, Nehmiz G, Krimmer J, Rösch W. Pharmacokinetics of meloxicam in patients with liver insufficiency associated with liver cirrhosis. Rheumatol Eur 1995;24(suppl. 3):177.